A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia

PHASE2CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

January 11, 2021

Primary Completion Date

December 28, 2021

Study Completion Date

March 3, 2022

Conditions
Hyperkalemia
Interventions
DRUG

RDX013

RDX013 is an experimental drug that is a potassium secretagogue

DRUG

Placebo

Placebo treatment that looks identical to experimental treatment

Trial Locations (6)

28801

Mountain Kidney & Hypertension Associates, Asheville

33014

Panax Clinical Research LLC, Miami Lakes

33134

Horizon Research Group LLC, Coral Gables

33166

South Florida Research Phase I-IV; Inc., Miami Springs

64111

Clinical Research Consultants, Kansas City

71101

NW Louisiana Nephrology Assoc, Shreveport

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ardelyx

INDUSTRY

NCT04780841 - A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia | Biotech Hunter | Biotech Hunter